Outcomes by Faricimab Treatment Interval at Week 48 of TENAYA-LUCERNE Phase III Trials in Neovascular Age-Related Macular Degeneration
Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Authors
- Nikolas London (ORCID: https://orcid.org/0000-0001-9809-6108)
- Jeffrey R. Willis (ORCID: https://orcid.org/0000-0002-6712-1144)
- Timothy Y. Y. Lai (ORCID: https://orcid.org/0000-0002-7832-6428)
- Aachal Kotecha (ORCID: https://orcid.org/0000-0003-4989-9216)
- Chui Ming Gemmy Cheung (ORCID: https://orcid.org/0000-0003-3358-3516)
- Philippe Margaron (ORCID: https://orcid.org/0000-0001-5215-3373)
- Stephan Michels (ORCID: https://orcid.org/0000-0002-3146-7805)
- Audrey Souverain
Institutions
- Roche (Switzerland) (CH)
- National University of Singapore (SG)
- Chinese University of Hong Kong (HK)
- University of Zurich (CH)
- Singapore National Eye Center (SG)
- California Retina Consultants (US)
- University Hospital of Zurich (CH)
- Roche (United Kingdom) (GB)
- Duke-NUS Medical School (SG)
Publication Details
- Journal
- Ophthalmology Retina
- Published
- 2025-05-09
- DOI
- https://doi.org/10.1016/j.oret.2025.05.004
- Citations
- 3
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 5.12
Funders
- F. Hoffmann-La Roche